16 results match your criteria Macular Edema Pseudophakic Irvine-Gass
Eur J Ophthalmol 2018 Mar 11;28(2):234-240. Epub 2017 Jan 11.
1 Department of Ophthalmology, Centre Hospitalier Intercommunal de Creteil University Paris Est Creteil, Creteil - France.
Purpose: To compare the optical coherence tomography angiography (OCT-A) findings of the superficial capillary plexus (SCP) and deep capillary plexus (DCP) in eyes with pseudophakic cystoid macular edema (PCME) with those of fluorescein angiography (FA) and spectral-domain optical coherence tomography (SD-OCT) and to compare PCME vascular density values of the SCP and DCP with those of healthy eyes.
Methods: In this retrospective observational study, 13 eyes (12 patients) with PCME underwent comprehensive ophthalmologic examinations including visual acuity, FA, SD-OCT, and OCT-A. The vascular density of the SCP and DCP were measured using AngioAnalytics software in all PCME eyes and compared with 46 healthy eyes of 25 subjects. Read More
Retin Cases Brief Rep 2018 Winter;12(1):59-62
Department of Ophthalmology, China Medical University Hospital, China Medical University, Taichung, Taiwan.
Background/purpose: To present the patient treated for pseudophakic cystoid macular edema with intravitreal aflibercept.
Methods: Interventional case report.
Case: An 83-year-old woman presented with decreased vision 1 month after uneventful cataract surgery. Read More
Eur J Ophthalmol 2016 Apr 12;26(3):e52-4. Epub 2016 Apr 12.
Department of Ophthalmology, Faculty of Medicine University Vita-Salute San Raffaele in Milan and University Hospital San Raffaele in Milan, Milan - Italy.
Purpose: Intravitreal implantation of dexamethasone implant (Ozurdex®) is being widely used for the treatment of macular edema (ME) after branch or central retinal vein occlusion, diabetic ME, and persistent ME associated with uveitis or Irvine-Gass syndrome. We describe a complication: migration of the dexamethasone implant into the anterior chamber through basal iridectomy (Ando) in a pseudophakic patient with development of corneal edema and secondary high intraocular pressure.
Methods: This is a case report of migration of Ozurdex® through basal iridectomy in a pseudophakic patient with iris claw lens. Read More
J Cataract Refract Surg 2015 Sep;41(9):1954-61
From the Department of Ophthalmology (Mayer, Kurz, Wolf, Kook, Kreutzer, Kampik, Priglinger, Haritoglou), Ludwig-Maximilians-University, and Herzog Carl Theodor Eye Clinic (Haritoglou), Munich, Germany; the Department of Ophthalmology (Kreutzer, Priglinger), Allgemeines Krankenhaus Linz, Linz, Austria.
Purpose: To investigate the effectiveness and safety of a dexamethasone implant (Ozurdex) to treat pseudophakic macular edema (Irvine-Gass syndrome).
Setting: Department of Ophthalmology, Ludwig-Maximilians-University Munich, Munich, Germany.
Design: Prospective nonrandomized study. Read More
Case Rep Ophthalmol 2015 Jan-Apr;6(1):143-8. Epub 2015 Apr 30.
Parke Street Specialist Centre, Katoomba, N.S.W., Australia.
Purpose: To report a case of acute bilateral Irvine-Gass syndrome.
Methods: This is an observational case report.
Results: An 82-year-old man with no significant ocular history developed postsurgical pseudophakic cystoid macular edema (CME; Irvine-Gass syndrome) on consecutive phacoemulsification cataract surgeries. Read More
Graefes Arch Clin Exp Ophthalmol 2016 Jan 12;254(1):43-51. Epub 2015 Apr 12.
Division of Retina and Vitreous, Ophthalmic Consultants of Long Island, 2000 North Village Avenue, suite 402, Rockville Centre, NY, 11570, USA.
Purpose: To describe the relationship between pseudophakic cystoid macular edema (CME) progression and retinal structural changes observed by spectral-domain optical coherence tomography (SD-OCT) and fluorescein angiography.
Methods: Retrospective, consecutive, longitudinal imaging analysis of patients with acute pseudophakic cystoid macular edema. Two observers at two study centers evaluated all images and categorized the macular structural features based on the retinal layer involved with cystic changes and/or subretinal fluid. Read More
Arch Soc Esp Oftalmol 2015 Jul 25;90(7):303-7. Epub 2015 Mar 25.
Servicio de Oftalmología, Hospital Universitario de La Ribera, Alzira, Valencia, España.
Objective: To evaluate the efficacy of intravitreal dexamethasone implant on the treatment of pseudophakic macular edema (PME).
Material And Methods: A retrospective, observational, descriptive study was conducted on 4 patients who received an intravitreal injection of dexamethasone implant due to PME in the period from 1st January 2013 to 31st December 2013 in the Hospital Universitario de La Ribera (Alzira, Valencia, Spain). A complete ophthalmic examination was performed on these patients. Read More
J Fr Ophtalmol 2015 Feb 13;38(2):126-33. Epub 2015 Jan 13.
Centre hospitalier national ophtalmologique des Quinze-Vingts, 28, rue de Charenton, 75012 Paris, France.
Introduction: The intravitreal dexamethasone implant has shown efficacy in the treatment of macular edema (ME) arising after retinal venous occlusions (central or branch), and in the treatment of non-infectious uveitis. The purpose of this study was to evaluate the efficacy of this implant in the treatment of other diffuse macular edemas with an inflammatory mechanism.
Materials And Methods: We carried out a retrospective cohort study over 2 years: from January 2012 to December 2013, including all patients who received at least one injection of intravitreal dexamethasone implant, excluding venous occlusions and non-infectious uveitis. Read More
Case Rep Ophthalmol 2014 May 4;5(2):243-8. Epub 2014 Aug 4.
Ophthalmology Unit, NESMOS Department, S. Andrea Hospital, Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Rome, Italy.
Purpose: To evaluate the efficacy of 2 dexamethasone intravitreal implants and 1 ranibizumab intravitreal injection after a bilateral postoperative complication of cataract surgery as pseudophakic cystoid macular edema.
Patients And Methods: A 70-year-old male patient with systemic hypertension developed a progressive cystoid macular edema (CME) in both eyes starting between 10 and 20 days after cataract surgery. Two intravitreal dexamethasone implants and 1 ranibizumab injection were administered; first in the right eye (RE) and then in the left eye (LE). Read More
Ocul Immunol Inflamm 2015 Jun 28;23(3):225-31. Epub 2014 Mar 28.
2nd Eye Clinic, "Ophthalmiatrion Athinon" Specialized Eye Hospital , Athens , Greece.
Purpose: The purpose of our study was to evaluate the potential efficacy and safety of intravitreal ranibizumab in patients with pseudophakic cystoid macular edema (CME).
Methods: This retrospective study comprised 7 eyes with CME treated with intravitreal ranibizumab. Patients were examined at 1 week and 1 month after injection and monthly thereafter. Read More
Clin Ophthalmol 2013 15;7:1437-9. Epub 2013 Jul 15.
1st Department of Ophthalmology, University of Athens, Athens, Greece.
Background: Macular edema (ME) is caused by abnormal retinal capillary permeability and has also been described as a postoperative complication of cataract surgery (Irvine-Gass syndrome).
Objective: To present a patient with Irvine-Gass syndrome in the right eye complicated with a macular hole (MH) in the same eye and possible associations between these two entities.
Case Report: A 72-year-old male with a history of uneventful bilateral cataract surgery was followed-up with biomicroscopy and optical coherence tomography (OCT). Read More
Clin Ophthalmol 2013 13;7:1171-4. Epub 2013 Jun 13.
Department of Ophthalmology, Copenhagen University Hospital Roskilde, Roskilde, Denmark ; Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark.
Background: Refractory pseudophakic cystoid macular edema (PCME) following cataract surgery has long posed a challenge to clinicians, but intravitreal injections with a sustained delivery 0.7 mg dexamethasone implant has emerged as a promising therapy for this condition.
Objective: To present a case of longstanding and refractory PCME with complete remission through 189 days of follow-up after two successive injections with intravitreal dexamethasone implants. Read More
J Ocul Pharmacol Ther 2012 Dec 25;28(6):636-9. Epub 2012 Jun 25.
Department of Ophthalmology, Ankara University Faculty of Medicine, Ankara, Turkey.
Purpose: To evaluate the functional and anatomical outcome after intravitreal ranibizumab injection in 2 patients with cystoid macular edema (CME) related to Irvine-Gass syndrome.
Methods: Two patients with pseudophakic CME refractory to current standard topical treatment were enrolled in this study. Intravitreal (0. Read More
Ocul Immunol Inflamm 2011 Jun;19(3):216-8
Centre for Ophthalmology, University of Tübingen, Tübingen, Germany.
Purpose: To describe treatment of chronic Irvine-Gass syndrome (CME) with interferon (IFN) alpha.
Methods: Interventional retrospective case series. IFN alpha-2a was administered at a dose of 3 million IU/day subcutaneously for 4 weeks, and was tapered thereafter. Read More
J Cataract Refract Surg 2008 Jan;34(1):70-5
University Eye Clinic Tuebingen, Centre of Ophthalmology, Eberhard-Karls University, Tuebingen, Germany.
Purpose: To describe the efficacy of intravitreal bevacizumab (Avastin) in patients with cystoid macular edema (CME) after cataract surgery (Irvine-Gass syndrome).
Methods: This retrospective case series comprised 16 eyes of 16 patients with CME after cataract surgery refractory to current standard treatment who received an injection of 1.25 mg intravitreal Avastin. Read More
Ocul Immunol Inflamm 2005 Jul-Aug;13(4):295-300
Department of Ophthalmology, National Taiwan University Hospital (NTUH), Taipei, Taiwan.
Purpose: To investigate clinical findings and ocular characteristics of sterile endophthalmitis following intravitreal injection (IVI) of triamcinolone for the treatment of macular edema.
Methods: IVI is an institutional practice at our hospital. From March 2002 to January 2003, a total of 21 IVIs of triamcinolone acetonide were performed on 19 patients with macular edema secondary to various retinal disorders. Read More